Abucay, Janet S.
HRN: 21-33-06 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/14/2022
CO-AMOXICLAV 625MG (TAB)
05/14/2022
05/20/2022
PO
625mg
BID
Acute Cystitis
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes